Showing 4161-4170 of 5996 results for "".
- Nivolumab Shows Promise in Advanced SCChttps://practicaldermatology.com/news/nivolumab-shows-promise-in-advanced-scc/2461399/Numerous studies have shown that immune checkpoint inhibitors can boost the immune system’s response against various cancers, and now, a phase II clinical trial has demonstrated that patients with advanced cutaneous squamous cell carcinoma can benefit from nivolumab. The research is publish
- Hair Straightening Chemicals Associated with Higher Uterine Cancer Riskhttps://practicaldermatology.com/news/hair-straightening-chemicals-associated-with-higher-uterine-cancer-risk/2461397/Chemical hair straighteners may be contributing to a rise in aggressive uterine cancers a new study in the Journal of the National Cancer Institute suggests. The
- Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosishttps://practicaldermatology.com/news/seborrheic-dermatitis-survey-shows-burdensome-and-lengthy-path-to-diagnosis/2461396/Arcutis Biotherapeutics, Inc., shared results of a nationwide survey of adults with seborrheic dermatitis and the health care providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease. The online survey was conducted by T
- Extreme Weather and Skin Disease: What’s the Connection?https://practicaldermatology.com/news/extreme-weather-and-skin-disease-whats-the-connection/2461395/As floods, wildfires, and extreme heat events increase in frequency and severity, they pose a significant threat to global dermatological health, as many skin diseases are climate sensitive, according to The Journal of Climate Change and Health. “We wanted to provide dermatol
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- U.S FDA Clears EndyMed’s Hair Removal Devicehttps://practicaldermatology.com/news/fda-clears-endymeds-hair-removal-device/2461393/The US Food and Drug Administration has cleared Endymed Ltd’s Pure Laser hair removal device for the marketing and sales. The Pure Laser was developed in the Company's labs by its subsidiary Endymed Medical Ltd. The Company intends to commence marketing in the US th
- Aesthetics Biomedical's Vivace Ultra Wins FDA Clearancehttps://practicaldermatology.com/news/aesthetics-biomedicals-vivace-ultra/2461390/The FDA has given the nod to Aesthetics Biomedical Inc.’s Vivace Ultra for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. An innovative reimagination and technical upgrade of the legacy Vivace Microneedle RF device, the Vivace Ultra comb
- Thirdhand Smoke Linked to Contact Dermatitis, Psoriasishttps://practicaldermatology.com/news/thirdhand-linked-to-contact-dermatitis-psoriasis/2461389/Acute exposure to thirdhand smoke on the skin elevates biomarkers associated with the initiation of skin diseases, such as contact dermatitis and psoriasis. “We found exposure of human skin to THS initiates mechanisms of inflammatory skin disease, and elevate
- Galderma's Alastin Rolls Out Pigment-Reducing A-LUMINATE BRIGHTENING SERUMhttps://practicaldermatology.com/news/galdermas-alastin-rolls-out-pigment-reducing-a-luminate-brightening-serum/2461386/Galderma’s ALASTIN Skincare is rolling out A-LUMINATE BRIGHTENING SERUM to help reduce the appearance of surface pigmentation without any harsh, irritating ingredients. A-LUMINATE BRIGHTENING SERUM contains a multifaceted blend of peptides, antioxidants, and targeted in
- Castle Bioscience’s DecisionDx-SCC Test Boosts Mohs Surgeons' Confidencehttps://practicaldermatology.com/news/castle-biosciences-decisiondx-scc-test-boosts-mohs-surgeons-confidence/2461382/Castle Bioscience’s DecisionDx-SCC test results can assist Mohs surgeons in making risk-aligned management plans and increase confidence in their treatment decisions, according to data presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. DecisionD